GlassScriptPhysician profile
Amanda Davenport
NPI 1174018857
$5,739.11
in general payments reported to CMS, 2019-2025
47 companies · $2,098 in 2025
The $2,098 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $446 · 2022: $750 · 2023: $1,220 · 2024: $1,225 · 2025: $2,098.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,343 · Long Term Medical Supply Or Device Loan: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,342.91 |
| Long Term Medical Supply Or Device Loan | $199.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $934.20 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $470.88 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $423.73 | 2022-2025 | Fasenra, Calquence, Imfinzi |
| Daiichi Sankyo INC. | $270.99 | 2023-2025 | Enhertu |
| Novo Nordisk INC | $188.49 | 2021-2022 | |
| Galvanize Therapeutics, INC | $151.30 | 2025 | Aliya System |
| Beigene USA, INC. | $145.52 | 2024-2025 | Brukinsa, Tevimbra |
| Takeda Pharmaceuticals U.S.A., INC. | $143.64 | 2023-2025 | Iclusig, Ninlaro, Alunbrig |
| Jazz Pharmaceuticals INC. | $133.20 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $132.72 | 2024-2025 | |
| Novocure INC. | $128.67 | 2025 | Optune Lua (Novottf-200t) |
| Mylan Specialty L.P. | $123.51 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $123.44 | 2025 | Libtayo, Lynozyfic |
| Incyte Corporation | $123.16 | 2023-2025 | Jakafi, Monjuvi, Zynyz |
| Astellas Pharma US INC | $122.53 | 2024-2025 | Vyloy, Padcev |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $118.77 | 2022-2025 | Jaypirca, Verzenio, Mounjaro |
| Lundbeck LLC | $118.04 | 2023 | Vyepti |
| Janssen Biotech, INC. | $114.10 | 2024-2025 | Darzalex, Talvey, Tecvayli |
| Glaxosmithkline, LLC. | $109.60 | 2023-2025 | Ojjaara, Jemperli |
| Kite Pharma, INC. | $107.15 | 2023 | |
| Exelixis INC. | $105.19 | 2024-2025 | Cabometyx |
| Horizon Therapeutics Plc | $99.84 | 2022 | |
| Amgen INC. | $99.41 | 2022-2023 | Blincyto, Kyprolis |
| Gilead Sciences, INC. | $93.53 | 2024-2025 | Trodelvy |
| Stemline Therapeutics INC. | $91.65 | 2023-2025 | Orserdu |
| Celgene Corporation | $91.13 | 2024-2025 | Reblozyl, Pomalyst |
| Genentech USA, INC. | $89.82 | 2021-2025 | Tecentriq |
| Aveo Pharmaceuticals, INC. | $86.06 | 2023-2025 | Fotivda |
| Eisai INC. | $71.11 | 2024 | |
| Adc Therapeutics America, INC. | $68.92 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $65.01 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $61.17 | 2024-2025 | Onivyde |
| Pharmacosmos Therapeutics INC. | $60.07 | 2025 | Monoferric |
| Tersera Therapeutics LLC | $57.96 | 2024 | Zoladex |
| Emd Serono, INC. | $54.72 | 2024-2025 | |
| Pfizer INC. | $54.35 | 2024-2025 | |
| Sobi, INC | $42.97 | 2025 | |
| Geron Corporation | $40.97 | 2025 | Rytelo |
| Genzyme Corporation | $37.33 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $36.60 | 2023-2024 | Augtyro, Opdualag |
| Taiho Oncology, INC. | $25.64 | 2025 | |
| Alexion Pharmaceuticals, INC. | $24.32 | 2024 | Ultomiris |
| Kyowa Kirin, INC. | $21.62 | 2025 | |
| Puma Biotechnology, INC. | $21.36 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.73 | 2024 | Gilotrif |
| Genmab U.S., INC. | $18.34 | 2025 | Epkinly |
| Merck Sharp & Dohme LLC | $16.65 | 2024 | Keytruda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Davenport listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.